Friday, November 9, 2012

Making progress with the HIV/AIDS vaccine

Western’s Schulich School of Medicine & Dentistry, with the support of Sumagen Canada, are preparing the steps to move forward with their Human HIV/AIDS vaccine trials. They have conducted Phase I studies without any harm reported and are now discussing Phase II and Phase III trials.

Developed by Dr. Chil-Yong Kang and histeam at Western’s Schulich School of Medicine & Dentistry, with the supportof Sumagen Canada, the vaccine (SAV001-H) holds tremendous promise for successin the final phases of clinical testing now that the first hurdle has beenaccomplished. It is the only HIV vaccine currently under development in Canada,and one of only a few in the world. The company hopes to collaborate with international biopharma companies in the future, which could lead clinical trial and commercialization opportunities around the world. 

How could this vaccine change both the pharmaceutical and healthcare industries forever? Want to learn more about the future of Clinical Trials? At Partnerships we have all the information needed to keep you updated with the latest research and development regarding clinical trials. Opt-in to receive the latest updates on live events, private industry events, webinars and whitepapers, and VIP promotions.

No comments: